Skip to contentO
Oncotelic Therapeutics, Inc.
O
OTLCOncotelic Therapeutics, Inc. Q3 2022 · 10-Q
Revenue—
Net Income-$777.94K-$777.94KN/M vs Q3 2021 EPS Diluted$0.00$0.00— vs Q3 2021 Operating Income-$595,439N/M Operating Cash Flowderived-$206,083N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oncotelic Therapeutics, Inc. · CIK 908259 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 18, 2022 · 49 d after period end